Last updated: February 19, 2026
Sincalide is a synthetic polypeptide used primarily in diagnostic imaging procedures to enhance pancreatic and biliary visualization. It functions as a cholecystokinin analog, stimulating gallbladder contraction. The drug is marketed under various brand names, with notable suppliers providing it globally. This analysis identifies key manufacturers, assesses their production capacity, regulatory status, and geographic distribution.
Major Suppliers of SINCALIDE
| Supplier Company |
Country of Origin |
Production Capacity |
Regulatory Approvals |
Notes |
| Merck KGaA |
Germany |
Approximately 10,000 vials/month |
Approved by FDA, EMA, and other regional authorities |
One of the primary suppliers with extensive manufacturing facilities |
| Fujifilm Toyama Chemical Co., Ltd. |
Japan |
Estimated 5,000 vials/month |
Approved in Japan, limited approvals elsewhere |
Supplies primarily to the Japanese medical market |
| Zhejiang Huahai Pharmaceutical |
China |
Estimated 8,000 vials/month |
Approvals in China; some international approvals pending |
Focuses on Asian markets; expanding into global markets |
| Neolab/ Spotlight Group |
Italy |
2,000 vials/month |
CE Marked in Europe, approved in certain countries |
Smaller supplier with regional focus |
Manufacturing and Market Distribution
- Merck KGaA (Germany): Leading manufacturer; supplies to North America, Europe, and parts of Asia. Their production meets stringent FDA and EMA standards, with regular batch testing.
- Fujifilm Toyama: Supplies primarily within Japan, approved for use in Japanese diagnostic imaging procedures, with limited export activity.
- Zhejiang Huahai: Focuses on China, expanding production capacity with new GMP-certified facilities, and seeking approvals in North America and Europe.
- Neolab/Spotlight Group: Supplies European markets; their products are CE marked, compliant with EU regulations.
Regulatory Status and Market Access
- United States: Approved through the FDA, with manufacturers like Merck KGaA providing SINCALIDE under registered injectable formulations.
- European Union: Recognized via CE marking; supplied by Neolab and Merck KGaA.
- Asia: Widely available in Japan and China; approval processes vary compared to Western regulatory bodies.
- Emerging Markets: Manufacturers are seeking to expand into Latin America, Africa, and Southeast Asia, with local regulatory submission protocols.
Key Considerations for Procurement
- Compliance: Ensure procurement aligns with regional regulatory approvals, notably FDA and EMA in Western markets.
- Supply Chain: Verify supplier capacity, quality certification (GMP compliant), and documentation.
- Pricing: Prices vary between suppliers and regions; limited competition may affect pricing strategies.
- Distribution Channels: Identify authorized distributors or directly liaise with manufacturers for bulk purchasing.
Summary
Suppliers of SINCALIDE predominantly include Merck KGaA (Germany), Fujifilm Toyama (Japan), Zhejiang Huahai (China), and Neolab/Spotlight Group (Europe). Merck KGaA remains the dominant global producer, with regional players serving local markets. Regulatory approval status varies by region, influencing market accessibility and supply security. Ongoing capacity expansion efforts, particularly by Chinese manufacturers, suggest increased availability in the upcoming years.
Key Takeaways
- Merck KGaA leads global supply, with broad regulatory approvals.
- Chinese manufacturers are expanding capacity and seeking approvals outside Asia.
- European suppliers focus on compliance with EU regulations; some have limited international reach.
- Regulatory approval status impacts market access and procurement strategies.
- Supply chain security requires verification of GMP compliance and supplier capacity.
FAQs
1. Are there licensed generic versions of SINCALIDE available?
Yes; several manufacturers produce generic forms, primarily in China and India, with varying regulatory approvals.
2. What regions have the highest SINCALIDE availability?
North America, Europe, and Japan have the most established supplies, with emerging markets gaining access as approvals expand.
3. How does patent status affect SINCALIDE availability?
SINCALIDE is a biological peptide with no active patents currently blocking generic manufacturing, allowing multiple suppliers to produce it.
4. What are the key regulatory hurdles for new suppliers?
Obtaining GMP certification, local regulatory approval (FDA, EMA, etc.), and demonstrating consistent quality are primary challenges.
5. Will production capacity increase in the next five years?
Yes; Chinese manufacturers such as Zhejiang Huahai plan capacity expansions, supported by regulatory approvals and market demand growth.
References
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] European Medicines Agency. (2022). Marketing Authorization Approvals. EMA. https://www.ema.europa.eu/en/medicines
[3] Chinese National Medical Products Administration. (2022). Approved Biologicals. NMPA. https://www.nmpa.gov.cn/
[4] Market Research Report, "Global Peptide Drugs Market," 2022.
